Amarin | AMRN - Actif À Court Terme





Actif À Court Terme Changement Date
AbbVie USD 29.06B 523M 2025-12
Alnylam Pharmaceuticals USD 4.05B 97.85M 2025-12
Amarin USD 649.88M 21.55M 2025-12
AstraZeneca USD 28.72B 1.22B 2025-12
BioCryst Pharmaceuticals USD 404.35M 48.66M 2025-12
DBV Technologies USD 88.88M 32.36M 2025-09
Esperion Therapeutics USD 462.57M 102.11M 2025-12
GlaxoSmithKline GBP 17.51B 332M 2025-12
Halozyme Therapeutics USD 825.21M 503.54M 2025-12
Heron Therapeutics USD 238.07M 8.67M 2025-12
Ionis Pharmaceuticals USD 2.99B 471.01M 2025-12
Nektar Therapeutics USD 266.27M 15.09M 2025-12
Neurocrine Biosciences USD 2.52B 364.3M 2025-12
Novartis USD 30.46B 2.26B 2025-12